RFL Rafael Holdings Inc Class B

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

$40.32  +0.03 (0.07%)
As of 04/14/2021 12:21:26 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Real Estate
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/27/2018
Outstanding shares:  15,635,882
Average volume:  51,238
Market cap:   $629,969,686
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75062E106
ISIN:        US75062E1064
Sedol:      BFWZ8G9
Valuation   (See tab for details)
PE ratio:   -32.58
PB ratio:   5.48
PS ratio:   140.74
Return on equity:   -14.22%
Net income %:   -383.71%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy